Characterizing Patient-Reported Outcome Data Availability for Oral Anticancer Therapies
The majority of oral anticancer therapy clinical trials collect PROs; however, there remains an opportunity for increased data availability. Further study is warranted to characterize factors influencing PRO reporting and to provide direction for optimizing timely PRO data availability.
Authors
- Ami Vyas (ORCID: https://orcid.org/0000-0002-2660-2494)
- Joshua Samuel (ORCID: https://orcid.org/0009-0008-1805-4708)
- Britny R. Brown (ORCID: https://orcid.org/0000-0001-9968-0349)
- John B. Bossaer (ORCID: https://orcid.org/0000-0002-6096-9687)
- Morgan Teeters (ORCID: https://orcid.org/0009-0000-2243-6436)
Institutions
- East Tennessee State University (US)
- Northwell Health (US)
- University of Rhode Island (US)
- Duke University Health System (US)
- Rhode Island College (US)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1200/op-25-00770
- Primary Topic
- Medication Adherence and Compliance
- Type
- article
- Field-Weighted Citation Impact
- 0.00